ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0690

Is AKI in COVID-19 Patients Associated with Increased Mortality?

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Muthuppalaniappan, Vasantha M., Whittington Hospital, London, London, United Kingdom
  • Ng, Jennifer, Whittington Hospital, London, London, United Kingdom
  • Sharratt, Phoebe, Whittington Hospital, London, London, United Kingdom
  • Sun, Kristi, Whittington Hospital, London, London, United Kingdom
  • Harber, Mark, Whittington Hospital, London, London, United Kingdom
Background

Acute kidney injury(AKI) affects 22% of hospitalised patients and is associated with a 21.9% increased risk of mortality in non COVID-19 admissions. Based on reports from China the rate of AKI in patients hospitalised with COVID-19 is 3-9%. The study’s objective was to identify AKI prevalence in COVID-19 patients and associated adverse outcomes.

Methods

This is a retrospective observational cohort study of patients admitted to hospital with positive COVID-19 PCR testing from 14th February to 7th May 2020. Demographic data, past medical history and blood results were obtained from health records. AKI was defined according to KDIGO criteria.

Results

383 patients (220 Male) were included in the final analysis, with an age range of 18-99 yrs(median 69 yrs). AKI occurred in 153(39.9%) patients (103 male), with a median age of 74 years. 111(72.5%) patients had AKI on admission, 42(27.5%) developed AKI while hospitalised. Average clinical frailty score (CFS) in the AKI group was 4. Median creatinine kinase in the AKI group was 213iu/L(IQR 149-1260). Of all 153 AKI patients;100(65.4%) were in Stage 1, 29(19%) in Stage 2 and 24(15.7%) in Stage 3. 14(9.2%) patients required renal replacement therapy (RRT) with 7(50%) becoming dialysis independent. 3 patients died and 4 transferred to specialist units for treatment whilst on RRT. Mean peak serum creatinine of 246umol/L was observed on Day 5 of admission and Day 11 of symptoms on average. 90/153(58.5%) patients had recovery of renal function. 40/76(53%) patients who required CPAP or mechanical ventilation respiratory support had evidence of AKI compared to 113/304(37%) of non-ventilated patients. Of all 153 AKI patients, 61(39%) deaths occurred compared to 43/228(19%) in the non-AKI group. This difference was significant, p<0.01, OR= 2.89 (95% CI: 1.81, 4.58) suggesting that patients with AKI had a 74% chance of increased death. Univariate analysis showed that age, males, baseline eGFR, albumin, CFS and Charlson comorbidity index were predictors of AKI. Multivariate analysis showed that independent predictors of AKI included males, Black and Asian race, baseline eGFR and albumin. An increase in baseline eGFR by 1ml/min in COVID-19 patients was associated with a 2.4% risk reduction in death, p<0.01, OR= 0.976 (95% CI: 1.02, 1.03).

Conclusion

AKI is a common finding and a poor prognosticator in patients with COVID-19.